C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scienc

C4 TherapeuticsApr 9 00:00 ET

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scienc

C4 TherapeuticsApr 8 00:00 ET

Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)

Yahoo FinanceMar 28 04:36 ET

C4 Therapeutics Initiates Stock Option Repricing for Retention

TipRanksMar 8 16:23 ET

Over $700 million! Merck joins hands with C4T (CCCC.US) to develop anti-cancer proteolytic therapy

On March 4, C4 Therapeutics (CCCC.US) announced a licensing and cooperation agreement with Merck of Germany

Zhitong FinanceMar 5 08:18 ET

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024

CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain MetastasisWATERTOWN, Mas

C4 TherapeuticsMar 5 00:00 ET